281 related articles for article (PubMed ID: 38279258)
21. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
22. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
Tella SH; Kommalapati A; Mahipal A
Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
[TBL] [Abstract][Full Text] [Related]
24. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.
Wang T; Zhang Q; Wang N; Liu Z; Zhang B; Zhao Y
Curr Med Chem; 2021; 28(16):3107-3146. PubMed ID: 33050856
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
26. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
27. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
Zhang CH; Li M; Lin YP; Gao Q
Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
[TBL] [Abstract][Full Text] [Related]
28. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
Reiter FP; Ben Khaled N; Ye L; Zhang C; Seidensticker M; Op den Winkel M; Denk G; Geier A; De Toni EN
Dig Dis; 2022; 40(5):565-580. PubMed ID: 34644705
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
[TBL] [Abstract][Full Text] [Related]
30. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.
Bresnahan E; Lindblad KE; Ruiz de Galarreta M; Lujambio A
Clin Cancer Res; 2020 Oct; 26(20):5276-5286. PubMed ID: 32327473
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in immunotherapy for hepatocellular carcinoma.
Khan AA; Liu ZK; Xu X
Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
[TBL] [Abstract][Full Text] [Related]
32. Changes in therapeutic options for hepatocellular carcinoma in Asia.
Ogasawara S; Koroki K; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Kato N
Liver Int; 2022 Aug; 42(9):2055-2066. PubMed ID: 34780081
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for hepatocellular carcinoma: Recent advances and future targets.
Yu SJ
Pharmacol Ther; 2023 Apr; 244():108387. PubMed ID: 36948423
[TBL] [Abstract][Full Text] [Related]
34. New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow.
Becht R; Kiełbowski K; Wasilewicz MP
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338736
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
36. Molecular therapies and precision medicine for hepatocellular carcinoma.
Llovet JM; Montal R; Sia D; Finn RS
Nat Rev Clin Oncol; 2018 Oct; 15(10):599-616. PubMed ID: 30061739
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular carcinoma, novel therapies on the horizon.
El Dika I; Makki I; Abou-Alfa GK
Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
[TBL] [Abstract][Full Text] [Related]
38. Advances in systemic therapy for the first-line treatment of unresectable HCC.
Vogel A; Bathon M; Saborowski A
Expert Rev Anticancer Ther; 2021 Jun; 21(6):621-628. PubMed ID: 33499684
[No Abstract] [Full Text] [Related]
39. Immunotherapy for advanced hepatocellular carcinoma, where are we?
Zhang L; Ding J; Li HY; Wang ZH; Wu J
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188441. PubMed ID: 33007432
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]